Maurizio Scaltriti Selected Research

Neoadjuvant Therapy

9/2021	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies.
12/2009	Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maurizio Scaltriti Research Topics

Disease

90	Neoplasms (Cancer) 05/2024 - 07/2003
50	Breast Neoplasms (Breast Cancer) 05/2024 - 04/2007
8	Triple Negative Breast Neoplasms 09/2021 - 11/2012
5	Neoplasm Metastasis (Metastasis) 01/2017 - 07/2003
5	Prostatic Neoplasms (Prostate Cancer) 11/2007 - 01/2004
4	Squamous Cell Carcinoma of Head and Neck 10/2020 - 04/2016
4	Disease Progression 01/2020 - 05/2012
3	Residual Neoplasm 09/2021 - 12/2009
3	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2018
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 01/2019
2	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 12/2015
2	Carcinogenesis 03/2016 - 11/2007
2	Carcinoma (Carcinomatosis) 11/2013 - 01/2004
1	Pneumonia (Pneumonitis) 03/2021
1	Inflammation (Inflammations) 03/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Exanthema (Rash) 01/2020
1	Diarrhea 01/2020
1	Hyperglycemia 01/2020

Drug/Important Bio-Agent (IBA)

25	Phosphotransferases (Kinase)IBA 01/2021 - 07/2006
19	Trastuzumab (Herceptin)FDA Link 05/2023 - 04/2007
17	Estrogen ReceptorsIBA 05/2024 - 11/2010
12	Proteins (Proteins, Gene)FDA Link 05/2023 - 06/2002
11	AlpelisibIBA 05/2024 - 07/2013
11	Biomarkers (Surrogate Marker)IBA 11/2022 - 12/2013
10	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 07/2006
9	Lapatinib (GW572016)FDA Link 01/2021 - 04/2007
8	human ERBB2 proteinIBA 01/2021 - 05/2010
8	ErbB Receptors (EGF Receptor)IBA 10/2018 - 09/2006
6	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 05/2024 - 07/2013
6	Hormones (Hormone)IBA 05/2024 - 09/2012
6	Protein Isoforms (Isoforms)IBA 01/2022 - 11/2007
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 09/2007
5	AntibodiesIBA 09/2021 - 07/2006
5	ClusterinIBA 11/2007 - 06/2002
4	Mitogen-Activated Protein KinasesIBA 01/2022 - 04/2007
4	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022 - 02/2015
4	Tyrosine Kinase InhibitorsIBA 01/2022 - 04/2007
4	ipatasertibIBA 01/2021 - 12/2013
4	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 05/2012
4	Fulvestrant (Faslodex)FDA Link 01/2020 - 04/2015
4	larotrectinibIBA 01/2019 - 01/2017
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 06/2013
3	ChromatinIBA 05/2024 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2022 - 06/2002
3	neratinibIBA 01/2021 - 10/2018
3	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2021 - 04/2016
3	Drug CombinationsIBA 01/2021 - 01/2013
3	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
3	RNA (Ribonucleic Acid)IBA 01/2019 - 10/2004
2	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2020
2	dinaciclibIBA 01/2021 - 11/2016
2	EnzymesIBA 01/2021 - 01/2017
2	Aromatase InhibitorsIBA 10/2020 - 01/2020
2	Transcription Factors (Transcription Factor)IBA 10/2020 - 11/2016
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2018
2	capivasertibIBA 01/2020 - 01/2020
2	Cell-Free Nucleic AcidsIBA 11/2019 - 01/2019
2	Cetuximab (Erbitux)FDA Link 01/2019 - 03/2014
2	entrectinibIBA 12/2018 - 11/2017
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2016 - 11/2012
2	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2016 - 03/2014
2	TOR Serine-Threonine KinasesIBA 01/2016 - 03/2015
2	NVP-BKM120IBA 03/2015 - 11/2012
2	ParaffinIBA 02/2014 - 04/2007
2	Everolimus FDA Link 07/2013 - 10/2008
2	AndrogensIBA 11/2007 - 09/2004
2	TeaIBA 09/2007 - 05/2006
1	Proteasome Endopeptidase Complex (Proteasome)IBA 05/2023
1	APOBEC-1 DeaminaseIBA 01/2023
1	Peptides (Polypeptides)IBA 01/2023
1	ribociclibIBA 01/2022
1	selpercatinibIBA 01/2022
1	trametinibIBA 01/2022
1	Macrophage Colony-Stimulating FactorIBA 01/2022
1	N-acetyltalosaminuronic acid (NAT)IBA 09/2021
1	Oxygen (Dioxygen)IBA 03/2021
1	canakinumab FDA Link 03/2021
1	A-1331852IBA 01/2021
1	tucatinibIBA 01/2021
1	GlycogenIBA 01/2021
1	UTP-Glucose-1-Phosphate Uridylyltransferase (UDP Glucose Pyrophosphorylase)IBA 01/2021
1	Apoptosis Regulatory ProteinsIBA 01/2021
1	Uridine Diphosphate (UDP)IBA 01/2021
1	S63845IBA 01/2021
1	Uridine Diphosphate Glucose (UDP Glucose)IBA 01/2021
1	Circulating Tumor DNAIBA 01/2020
1	Cytotoxins (Cytolysins)IBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2020
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020
1	trastuzumab deruxtecanIBA 01/2020
1	AfatinibIBA 01/2019
1	Lysine (L-Lysine)FDA Link 01/2019

Therapy/Procedure

56	Therapeutics 05/2024 - 09/2006
9	Drug Therapy (Chemotherapy) 01/2021 - 10/2004
4	Immunotherapy 01/2022 - 01/2018
2	Neoadjuvant Therapy 09/2021 - 12/2009
2	Aftercare (After-Treatment) 07/2013 - 05/2012
1	Precision Medicine 04/2021
1	Artificial Respiration (Mechanical Ventilation) 03/2021